Accession Number:



Enhancing the Immunogenicity of a Tetravalent Dengue DNA Vaccine

Descriptive Note:

Technical Report,15 Jul 2015,14 Jul 2016

Corporate Author:

Henry M. Jackson Foundation For the Advance of Military Rockville United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Dengue fever ranks among the top infectious diseases that afflict US Military personnel deployed overseas. Developing a successful vaccine to prevent dengue fever in DoD personnel is priority research area for the US DoD. Phase 1 clinical trials demonstrated that the Naval Medical Research Centers DNA based dengue vaccine is safe and well tolerated, but does not elicit a sufficient immune response. The objectives of this project are to conduct studies in non-human primates to enhance the immunogenicity of the vaccine by a testing different modes of delivery of dengue DNA vaccine for optimal humoral and T cell responses, and b testing the optimal delivery method in conjunction with other vaccine platforms using a heterologous prime-boost regimen. All necessary contracts are in place, the vaccine product is ready and the first vaccinations to address objective a are scheduled for early October 2016.

Subject Categories:

Distribution Statement: